NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
October 07, 2020 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were presented at the virtual 88th Annual...
Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
September 28, 2020 16:06 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed at...
Esperion to Participate in Two Upcoming Virtual Investor Conferences
September 02, 2020 08:41 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the...
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
August 10, 2020 16:04 ET
|
Esperion Therapeutics, Inc.
– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue – – Strong Capital Position with over $300 Million in Cash – – Extraordinary High-Quality...
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
August 03, 2020 07:26 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets on...
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
June 04, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with...
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc.
May 10, 2018 12:08 ET
|
Federman & Sherwood
OKLAHOMA CITY, May 10, 2018 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on May 7, 2018, a class action lawsuit was filed in the United States District Court for the District of...
Hagens Berman Reminds Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
March 07, 2016 08:30 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 07, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors there is a March...
SECURITIES NOTICE: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important March 14, 2016 Deadline in Class Action – ESPR
March 04, 2016 15:30 ET
|
The Rosen Law Firm PA
NEW YORK, March 04, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Esperion Therapeutics, Inc. securities (NASDAQ:ESPR) from August 18, 2015...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics, Inc. -- ESPR
February 11, 2016 16:40 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Esperion Therapeutics, Inc....